Radiation-induced tumors in irradiated stage I testicular seminoma: Results of a 25-year follow-up (1968–1993)

Author(s):  
Moshe E. Stein ◽  
Michelle Leviov ◽  
Keren Drumea ◽  
Boaz Moshkovitz ◽  
Ofer Nativ ◽  
...  
2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii335-iii335
Author(s):  
Takahiro Yamamoto ◽  
Keishi Makino ◽  
Hideo Nakamura ◽  
Jun-ichiro Kuroda ◽  
Takashi Itoyama ◽  
...  

Abstract INTRODUCTION Central nervous system germ cell tumor (GCT) is one of the pediatric brain tumors. Although there have been epidemiological studies in the past, long-term prognosis and the late effects remained unclear. In this study, we examined GCT over the past 41 years in Kumamoto prefecture. METHODS Epidemiological features and complications with radiation-induced tumors were searched in patients diagnosed with GCT in the 41-year period from 1977 to 2018. RESULTS There were 93 patients diagnosed with GCT. These cases were divided into 14-year periods before and after incorporation of chemotherapy into the treatment, and the results for germinomas were compared. An improvement in the 10-year survival rate from 12 of 23 cases (52.2%) between 1977 and 1991 to 19 of 28 cases (67.9%) between 1992 and 2006 was observed. The 10-year survival rate for germinoma cases that received medical treatment during a more recent 5-year period between 2004 and 2009 increased to over 90%. However, 10.3% of all long-term survivors of GCT developed radiation-induced glioblastoma. The examination results showed that regardless of the tumor type, patients who received a high dose of radiation during their initial treatment developed the complication of radiation-induced glioblastoma within 10 to 25 years after their initial treatment. CONCLUSION This study suggests that the long-term survival rates for GCT are improving but the rate of radiation-induced glioblastoma in these cases are too high to be ignored. Long-term follow-up of at least 10 years is essential to effectively evaluate the details of treatment for pediatric brain tumors.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4558-4558
Author(s):  
Konstantinos Koutsoukos ◽  
Michael Liontos ◽  
Maria Lykka ◽  
Georgios Rigakos ◽  
Anna Andreadou ◽  
...  

4558 Background: Adjuvant chemotherapy is used in stage I testicular seminoma. We have reported a risk-adapted strategy of 2 cycles of cisplatin/etoposide (EP) in 64 patients with age < 34 and/or tumor diameter > 4cm) (Bamias et al, Urology 2007), resulting in no relapses over a median follow up of 5 years. Following the establishment of adjuvant carboplatin as a standard, we adopted this treatment for all patients with stage I seminoma. We report our 8-year experience and compare these results with our previous EP strategy. Methods: Patients with stage I seminoma, treated with 2 cycles of carboplatin AUC 6 and a minimum follow up of 1 year after chemotherapy were selected. All patients consented for the use of their medical information and the analysis was approved by the centers involved. Survival functions were presented using Kaplan-Meier curves. The log-rank test was used to test for survival differences across different categories. Results: 137 patients (Median age: 34; Age<34: 49%, tumor diameter>4cm: 42%; rete testis invasion: 24%), treated between 11/2003-12/2011 were selected. During a median follow up of 4 years, there were 5 relapses (5-y relapse rate [RR]: 97% [SE: 2%]): retroperitoneal lymph nodes (n=4) and isolated brain (n=1). All patients with relapse had tumor diameter > 4cm and/or age < 34. No relapse was associated with rete testis invasion. Patients with at least 1 of the above risk factors (n=94) had a significantly higher relapse rate compared with a similar population (n=64) treated with 2 cycles of adjuvant EP: 5-y RR was 95% (SE: 2%) vs.100% (SE 0%), (p=0.033). All relapsed patients were treated with BEP chemotherapy and are currently alive with no evidence of relapse. Neutropenia and nausea/vomiting were less frequent with carboplatin than with EP (11% vs. 36% and 15% vs. 65%). Conclusions: Our analysis confirms the association of age and tumor diameter with relapse in stage I seminoma treated with adjuvant carboplatin. Although adjuvant carboplatin in patients with age<34 and/or tumor diameter> 4 cm is associated with higher RR than EP, the prognosis of these patients is excellent with salvage chemotherapy and, therefore, the use of less toxic treatment is justified.


1993 ◽  
Vol 53 (3) ◽  
pp. 175-179 ◽  
Author(s):  
Moshe Efraim Stein ◽  
Ivan Kessel ◽  
Norman Luberant ◽  
Avraham Kuten

1981 ◽  
Vol 31 (2) ◽  
pp. 233-247
Author(s):  
Fumitoshi Chino ◽  
Fumiaki Sato ◽  
Shunsaku Sasaki

Neurosurgery ◽  
1989 ◽  
Vol 25 (4) ◽  
pp. 643-645 ◽  
Author(s):  
K. Sridhar ◽  
B. Ramamurthi

Abstract The authors report a case of an intracranial meningioma that developed 33 years after radiation therapy for a pituitary tumor. Radiation-induced tumors form a distinct biological group with aggressive growth characteristics and a malignant potential.


2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Ryuji Okazaki ◽  
Akira Ootsuyama ◽  
Yasuhiro Yoshida ◽  
Toshiyuki Norimura

Methylation-specific PCR (MSP) of the mouse p53 gene has not yet been reported. We searched the CpG islands, sequenced the bisulfited DNA, and designed PCR primers for methylation and unmethylation sites. DNA from a young mouse produced a strong PCR product with the unmethylated primer and a weaker band with the methylated primer. DNA from an old mouse produced bands of similar intensities with both primers. In radiation-induced tumors, DNA from an old mouse yielded similar bands with both types of primers. We suggest that MSP is a valuable technique for the epigenetic study of the mouse p53 gene.


1975 ◽  
Vol 7 (1) ◽  
pp. 57-61
Author(s):  
M. B. Patricio ◽  
W. H. Clode ◽  
J. A. Ricardo

Sign in / Sign up

Export Citation Format

Share Document